To include your compound in the COVID-19 Resource Center, submit it here.

ALKS 33: Development discontinued

Alkermes discontinued development of ALKS 33 to treat binge eating disorder after data from a double-blind, U.S. Phase II trial in 68 patients

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE